Dyne Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 5, 2024. Dyne is a clinical-stage biotechnology company developing oligonucleotide therapeutics for genetically driven muscle diseases using its FORCE delivery platform. It had no approved products and generated no revenue.
Financial performance and position
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | None | None | No product revenue |
| Research and development expense | $210.8 million | $142.8 million | Up $68.0 million |
| General and administrative expense | $31.4 million | $28.2 million | Up $3.2 million |
| Total operating expenses / operating loss | $242.2 million | $171.0 million | Expense and loss increased $71.2 million |
| Net loss | $235.9 million | $168.1 million | Loss increased $67.8 million |
| Net loss per share, basic and diluted | $3.95 | $3.23 | Loss per share increased |
| Net cash used in operating activities | $188.2 million | $153.6 million | Use increased $34.5 million |
- Cash and liquidity: At year-end, cash and cash equivalents were $121.6 million and marketable securities were $1.5 million, totaling $123.1 million. Restricted cash was $2.3 million. Total assets were $165.1 million; stockholders’ equity was $91.3 million.
- Financing: FY2023 financing activities provided $54.3 million, including $52.4 million net proceeds from at-the-market share sales. In January 2024, the company raised a further $323.9 million net in a public offering. Management expects available funds, including those proceeds, to support operating and capital needs through 2025; this estimate depends on assumptions that may change.
- Debt and obligations: The filing reports no borrowings in the presented balance sheet. Lease liabilities totaled $27.4 million, including $4.7 million current and $22.7 million non-current. The company leases its Waltham office and laboratory facility.
- Margins: Not meaningful because the company had no revenue. Interest income was $7.6 million, versus $2.9 million in 2022; other expense, net, was $1.4 million.
Material changes and developments
- Net loss increased as R&D spending rose, principally due to increased clinical-trial activity and manufacturing for DYNE-101 and DYNE-251, along with higher R&D headcount.
- DYNE-101 direct program expense increased to $67.1 million from $31.3 million; DYNE-251 expense rose to $63.9 million from $48.4 million.
- Operating cash use rose to $188.2 million from $153.6 million. Cash, cash equivalents and restricted cash declined by $50.5 million during 2023.
- Common shares outstanding at December 31, 2023 were 61.5 million, compared with 55.6 million a year earlier. The January 2024 offering added 19.7 million shares; 81.96 million shares were outstanding as of February 29, 2024.
Pipeline, outlook and key risks
- DYNE-101 (DM1): In an ongoing Phase 1/2 trial, initial data announced in January 2024 showed dose-related DMPK knockdown and splicing correction, and a mean 3.8-second improvement in myotonia at six months in the 1.8 mg/kg every-four-weeks cohort. The company reported a generally favorable initial safety profile; liver enzyme elevations occurred in approximately 18% of participants, with no reported impact on liver function. Higher-dose cohort data were expected in the second half of 2024, and the company aimed to initiate registrational cohorts by year-end 2024.
- DYNE-251 (DMD): Initial Phase 1/2 data announced in January 2024 showed dystrophin expression, exon skipping and dystrophin-positive fibers at six months. The company compared results with a separate eteplirsen trial, but explicitly cautioned that the studies were not head-to-head and may not be directly comparable. Higher-dose cohort data were expected in the second half of 2024, with registrational cohorts targeted by year-end 2024.
- FSHD: The IND submission for DYNE-301 had been deferred while the company prioritized its DM1 and DMD clinical programs. Dyne planned to update its FSHD program in 2024.
- Other outlook: Dyne expects substantial operating losses and increased expenses as it advances its clinical programs and platform. It will need additional funding if development and operating needs exceed available resources; future financing could dilute shareholders or require licensing rights on unfavorable terms.
- Principal risks: Clinical candidates remain early-stage and may fail or be delayed; initial clinical findings may not predict later results; the FORCE platform is unproven; trials may face enrollment or safety challenges; and the company depends on third parties, including a limited number of suppliers and manufacturers. Regulatory approval, reimbursement, competition, intellectual-property protection and access to capital are also material uncertainties.
Important facts for investors to verify
- Current cash, burn rate and runway against management’s projection through 2025, including the impact of the January 2024 offering and increased share count.
- Subsequent ACHIEVE and DELIVER trial results, especially dose response, durability, functional outcomes and safety, and whether planned registrational cohorts proceed on schedule.
- How clinical results compare with appropriate controls; cross-trial comparisons with existing therapies are not direct evidence of comparative benefit.
- Manufacturing capacity, supply continuity and the ability of third-party suppliers to meet clinical and potential commercial needs.
- Progress and resourcing of the deferred FSHD program, and any changes to the company’s financing plans or expected cash runway.